(secondQuint)Effect of Squalamine Lactate Ophthalmic Solution, 0.

2% in Subjects With Neovascular Age-Related Macular Degeneration.

 Subjects with age-related macular degeneration who meet inclusion and exclusion criteria will be randomized to receive monthly intravitreal injections of ranibizumab (Lucentis(R)) with either Squalamine Lactate Ophthalmic solution 0.

2% or placebo eye drops twice a day for 6 months.

 Subjects will be evaluated with clinical and imaging techniques.

.

 Effect of Squalamine Lactate Ophthalmic Solution, 0.

2% in Subjects With Neovascular Age-Related Macular Degeneration@highlight

The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.

2% administered twice daily with monthly ranibizumab intravitreal injections in patients with choroidal neovascularization due to AMD.

